氘可来昔替尼治疗银屑病的试验数据

The purpose of this study was to demonstrate that colexitinib is more effective than placebo and apremilast in moderate to severe plaque psoriasis based on a ≥75% reduction from baseline in psoriasis area and severity index and a static physician global assessment score of 0 (clear) or 1 (mostly clear) with an improvement of ≥2 points from baseline at week 16.

research methods

The POETYK Psoriasis Phase 2 trial (NCT03611751) was a 52-week, double-blind Phase 3 trial that randomized patients 2:1:1 to 6 mg of apremilast daily (n = 511), placebo (n = 255), or 30 mg of apremilast twice daily (n = 254).

Test results

At Week 16, more colexitinib-treated patients had a ≥75% reduction from baseline in the Psoriasis Area and Severity Index compared with placebo and apremilast patients (53.0% vs 9.4% and 39.8%; P < .0001 vs placebo; P = .0004 vs apremilast) and achieved a Static Physician Global Assessment score of 0 or 1 (49.5% vs 8.6% and 33.9%; P < .0001). The efficacy of deuterated colexitinib can be maintained until week 52.

Safety of deuterated colexitinib in trial

The most common adverse reaction of deuterated colexitinib is nasopharyngitis. Serious and discontinuation due to adverse events are uncommon. No clinically significant changes in laboratory parameters were observed.

Test conclusion

Deuterated colexitinib was more effective than placebo and apremilast and was well tolerated in adults with moderate-to-severe plaque psoriasis.

What are the effects of deuterated colexitinib?

Deuterated colexitinib works by inhibiting the specific apoptosis-activated protein kinase (JAK) signaling pathway. Deuterated coxitinib can treat some autoimmune diseases by inhibiting the regulation of cytokine signaling on the activity of T cells, natural killer cells and immune regulatory cells. It is an oral JAK inhibitor.

Deuterated colexitinib has been evaluated in multiple clinical trials and demonstrated good efficacy and safety. In a study on psoriasis, researchers found that patients treated with deuterated colexitinib had a significant reduction in skin psoriasis area after 6 weeks, and most patients' symptoms improved significantly.

Where to purchase deuterated colexitinib

Deuterated colexitinib has been launched in mainland China, and there are two main purchase channels for patients:

1. It can be purchased at domestic hospital pharmacies or at qualified pharmacies or hospital pharmacies to ensure the quality and source of the medicine.

2. Obtain it through domestic professional overseas medical service organizations (such as Medical Companion Travel). The medicine can be mailed to your home. It is guaranteed to be genuine, affordable and cost-effective. The price is subject to various factors and is not fixed. It is recommended to consult customer service personnel for specific costs and acquisition procedures.

It should be noted that when purchasing any prescription medication, caution is required to ensure that it is purchased from a reliable source and used correctly according to the doctor's instructions.

Recommended related articles:

References

Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14. PMID: 36115523.